Warning: The NCBI web site requires JavaScript to function. more...
An official website of the United States government
The .gov means it's official. Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.
The site is secure. The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.
Antiviral activity against R5 tropic HIV-1 subtype-B Bal infected in human MT2 cells or CEMx174 5.25 M7 cells assessed as reduction in p24 Gag protein production at 12:1 ratio of hCS6ERE to compound measured at 4 days post-infection by ELISA
Assay data:1 Active, 1 Activity ≤ 1 nM, 1 Activity ≤ 1 µM, 1 Tested
SummaryCompounds, ActiveCompounds, activity ≤ 1 µMPubMed Citation
Antiviral activity against R5 tropic HIV-1 subtype-B Bal infected in human MT2 cells or CEMx174 5.25 M7 cells assessed as reduction in p24 Gag protein production at 6:1 ratio of hCS6ERE to compound measured at 4 days post-infection by ELISA
Antiviral activity against R5 tropic HIV-1 subtype-B Bal infected in human MT2 cells or CEMx174 5.25 M7 cells assessed as reduction in p24 Gag protein production at 3:1 ratio of hCS6ERE to compound measured at 4 days post-infection by ELISA
Assay data:1 Active, 1 Activity ≤ 1 µM, 1 Tested
Antiviral activity against R5 tropic HIV-1 subtype-B Bal infected in human MT2 cells or CEMx174 5.25 M7 cells assessed as reduction in p24 Gag protein production at 12:1 ratio of compound to HP23 measured at 4 days post-infection by ELISA
Antiviral activity against R5 tropic HIV-1 subtype-B Bal infected in human MT2 cells or CEMx174 5.25 M7 cells assessed as reduction in p24 Gag protein production at 6:1 ratio of compound to HP23 measured at 4 days post-infection by ELISA
Antiviral activity against R5 tropic HIV-1 subtype-B Bal infected in human MT2 cells or CEMx174 5.25 M7 cells assessed as reduction in p24 Gag protein production at 3:1 ratio of compound to HP23 measured at 4 days post-infection by ELISA
Antiviral activity against X4 tropic HIV-1 subtype-B 3B infected in human MT2 cells or CEMx174 5.25 M7 cells assessed as reduction in p24 Gag protein production at 24:1 ratio of hCS6ERE to compound measured at 4 days post-infection by ELISA
Antiviral activity against X4 tropic HIV-1 subtype-B 3B infected in human MT2 cells or CEMx174 5.25 M7 cells assessed as reduction in p24 Gag protein production at 12:1 ratio of hCS6ERE to compound measured at 4 days post-infection by ELISA
Antiviral activity against X4 tropic HIV-1 subtype-B 3B infected in human MT2 cells or CEMx174 5.25 M7 cells assessed as reduction in p24 Gag protein production at 6:1 ratio of hCS6ERE to compound measured at 4 days post-infection by ELISA
Antiviral activity against X4 tropic HIV-1 subtype-B 3B infected in human MT2 cells or CEMx174 5.25 M7 cells assessed as reduction in p24 Gag protein production at 24:1 compound to HP23 ratio measured at 4 days post-infection by ELISA
Antiviral activity against X4 tropic HIV-1 subtype-B 3B infected in human MT2 cells or CEMx174 5.25 M7 cells assessed as reduction in p24 Gag protein production at 12:1 compound to HP23 ratio measured at 4 days post-infection by ELISA
Antiviral activity against X4 tropic HIV-1 subtype-B 3B infected in human MT2 cells or CEMx174 5.25 M7 cells assessed as reduction in p24 Gag protein production at 6:1 compound to HP23 ratio measured at 4 days post-infection by ELISA
Antiviral activity against R5 tropic HIV-1 subtype-B Bal infected in human MT2 cells or CEMx174 5.25 M7 cells assessed as reduction in p24 Gag protein production measured at 4 days post-infection by ELISA
Assay data:5 Active, 5 Activity ≤ 1 µM, 5 Tested
Antiviral activity against X4 tropic HIV-1 subtype-B 3B infected in human MT2 cells or CEMx174 5.25 M7 cells assessed as reduction in p24 Gag protein production measured at 4 days post-infection by ELISA
Ratio of EC50 for antiviral activity against R5 tropic HIV-1 subtype-B Bal infected in human MT2 cells or CEMx174 5.25 M7 cells in absence of hCS6ERE to EC50 for antiviral activity against R5 tropic HIV-1 subtype-B Bal infected in human MT2 cells or CEMx174 5.25 M7 cells at 24:1 ratio of hCS6ERE to compound
Assay data:1 Tested
SummaryPubMed Citation
Ratio of EC50 for antiviral activity against R5 tropic HIV-1 subtype-B Bal infected in human MT2 cells or CEMx174 5.25 M7 cells in absence of hCS6ERE to EC50 for antiviral activity against R5 tropic HIV-1 subtype-B Bal infected in human MT2 cells or CEMx174 5.25 M7 cells at 12:1 ratio of hCS6ERE to compound
Ratio of EC50 for antiviral activity against R5 tropic HIV-1 subtype-B Bal infected in human MT2 cells or CEMx174 5.25 M7 cells in absence of hCS6ERE to EC50 for antiviral activity against R5 tropic HIV-1 subtype-B Bal infected in human MT2 cells or CEMx174 5.25 M7 cells at 6:1 ratio of hCS6ERE to compound
Ratio of EC50 for antiviral activity against R5 tropic HIV-1 subtype-B Bal infected in human MT2 cells or CEMx174 5.25 M7 cells in absence of HP23 to EC50 for antiviral activity against R5 tropic HIV-1 subtype-B Bal infected in human MT2 cells or CEMx174 5.25 M7 cells at 24:1 compound to HP23 ratio
Ratio of EC50 for antiviral activity against R5 tropic HIV-1 subtype-B Bal infected in human MT2 cells or CEMx174 5.25 M7 cells in absence of HP23 to EC50 for antiviral activity against R5 tropic HIV-1 subtype-B Bal infected in human MT2 cells or CEMx174 5.25 M7 cells at 12:1 compound to HP23 ratio
Ratio of EC50 for antiviral activity against R5 tropic HIV-1 subtype-B Bal infected in human MT2 cells or CEMx174 5.25 M7 cells in absence of HP23 to EC50 for antiviral activity against R5 tropic HIV-1 subtype-B Bal infected in human MT2 cells or CEMx174 5.25 M7 cells at 6:1 compound to HP23 ratio
Filters: Manage Filters
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on